Abstract
Human interferons (IFN) are antiviral proteins classified into three types: α, β, and γ (Isaacs et al, 1957; Lengyel, 1982; Stewart, 1979; Strander, 1982f). Work in bacteria, including genetic analysis and purification by monoclonal antibodies, has shown that a least 15 types of human IFNs exist. The biologic implication of this fact remains to be established.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Adamson, U., Aparisi, T., Broström, L.-Å., Cantell, K., Einhorn, S., Hall, K., Ingimarsson, S., Nilsonne, U., Strander, H., and Söderberg, G.: Interferon treatment of human osteosarcoma. Pontificiae Acad. Scient. Scripta Varia 43, 383, 1979a.
Adamson, U., Aparisi, T., Broström, L.-Å., Cantell, K., Einhorn, S., Hall, K., Ingimarsson, S., Nilsonne, U., Strander, H., and Söderberg, G.: Adjuvant interferon treatment of human osteosarcoma. In, Recent Results in Cancer Research. Eds.: G. Bonnadonna, G. Mathé and S.E. Salmon. Springer-Verlag, Berlin/Heidelberg, 68, 40, 1979b.
Aparisi, T., Strander, H., Broström, L.-Å., and Nilsonne, U.: Experience avec l’interferon dans le traitement de l’osteosarcome. Proc. of the Journées Annuelle de Chirurgie Orthopedique. Ed.: J. Duparc, 1981. (In press)
Ban, S., Yamagiwa, T., Yanagawa, T., Sakakida, K., Ito, H., Murakami, K., Matsuo, A., Imanishi, J., and Kishida, T.: Effect of human leukocyte interferon on metastatic lung tumor of osteosarcoma and primary lung cancer. In, The Clinical Potential of Interferon. Eds.: R. Kono and J. Vilćek. University of Tokyo Press, pp 223, 1982.
Berthold, W., Grazia-Masucci, M.-G., Klein, E., and Strander, H.: Interferon treatment elevates the cytotoxic potential of lymphocytes and thereby increases the frequency of functional killer cells. Human Lymphocyte Differentiation 1, 1, 1981.
Bloom, B.R.: Interferons and the immune system. Nature 285, 593, 1980.
Borden, E.C., and Hawkins, J.J.: Interferons for human neoplastic and viral diseases. Comprehensive Therapy, Harvard MA, 6, 6, 1980.
Broström, L.-Å.; On the natural history of osteosarcoma. Aspects on diagnosis, prognosis and endocrinology. Acta Orthop. Scand., Suppl. No. 183, 1979.
Broström, L.Å., Aparisi, T., Ingimarsson, S., Lagergren, C., Nilsonne, U., strander, H., and Söderberg, G.: Can historical controls be used in current clinical trials in osteosarcoma? Metastases and survival in a historical and a concurrent group. Int. J. Rad. Oneal. Biol. Phys. 6, 1717, 1980a.
Broström, L.-Å., Aparisi, T., Ingimarsson, S., Lagergren, C., Nilsonne, U., Strander, H., and Söderberg, G.: Can historical controls be used in current clinical trials in osteosarcoma? Analysis of prognostic factors. Int. J. Rad. Oncol. Biol. Phys. 6, 1711, 1980b.
Broström, L.-Å., Ingimarsson, S., Strander, H. and Eklund, G.: Correlation between prognostic factors and blood variables in osteosarcoma. Acta Hed. Scand. 207, 429, 1980c.
Broström, L.-Å., Ingimarsson, S., Strander, H., and Söderberg, G.: Adjuvant interferon treatment and late development of cerebral metastases in a patient with osteosarcoma. Acta Orthop. Scand. 51, 589, 1980d.
Broström, L.-Å., Strander, H., and Nilsonne, U.: Survival in osteosarcoma in relation to tumour size and location. Clin. Orthop. 167, 250, 1982.
Brouty-Boyé, D.: Inhibitory effects of interferons on cell multiplication. Lymphokine Reports 1, 99, 1980.
Cantell, K., Hirvonen, S., Kauppinen, H.L. and Myllylä, G.: Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods in Enzymology (New York) 78, 29, 1981.
Cantell, K., and Strander, H.: Human leukocyte interferon for clinical use. In, Blood Leukocytes. Functions and Use in Therapy. Eds.: C.F. Högman, K. Lindahl-Kiessling, and H. Wigzell. Almqvist and Wichzell, pp 73, 1977.
Einhorn, S.: Influence of interferon on human lymphocytes. In vitro and in vivo studies on spontaneous cytotoxicity and cell surface receptors. Thesis, Sundt Offset, Stockholm, 1980.
Einhorn, S. and Strander, H.: Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J. Gen. Virol. 35, 573, 1977.
Einhorn, S. and Strander, H.: Interferon therapy for neoplastic diseases in man. In, Production of Human Interferon and Investigations of Its Clinical Use. A Symposium Workshop, May 19–20, 1977. Human Interferon. Eds.: Warren R. Stinebring and Paul J. Chapple. Plenum Publ. Corp. 159, 1978a.
Einhorn, S., Blomgren, H., and Strander, H.: Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int. J. Cancer 22, 405, 1978b.
Einhorn, S., Blomgren, H., Cantell, K., and Strander, H.: Effect of prolonged in vivo administration of leukocyte interferon on the mitogen responsiveness of human lymphocytes. Acta Med. Scand. 206, 345, 1979.
Einhorn, S., Blomgren, H. and Strander, H.: Effect of an intramuscular injection of human leukocyte interferon on blood leukocyte counts and proportions of lymphocytes forming E, EA and EAC rosettes. Int. Arch. Allergy Appl. Immun. 63, 139, 1980a.
Einhorn, S., Blomgren, H., and Strander, H.: Interferon and spontaneous cytotoxicity in man. V. Enhancement of spontaneous cytotoxicity in patients receiving human leukocyte interferon. Int. J. Cancer 26, 419, 1980b.
Einhorn, S., Blomgren, H. and Strander, H.: Influence of interferon on the immune system. Proc. XIth Cong. Europ. Allergolog. Clin. Immunology, Vienna, October 6–10, 1980. In, Clinical Immunology and Allergology. Eds.: C. Steffan and H. Ludwig, Elsevier/North Holland Biomedical Press. 1981.
Einhorn, S., Ahre, A., Blomgren, H., Johansson, B., Mellstedt, H., and Strander, H.: Enhanced NK activity in patients treated by interferon-α. Relation to clinical response. In, Natural Cell-Mediated Immunity Against Tumours. In, NK Cells and Other Natural Effector Cells. Ed.: R.B. Herberman, Academic Press, 1259, 1982a.
Einhorn, S., Blomgren, H., Jarstrand, C., Strander, H., and Wasserman, J.: Influence of interferon-α therapy on different functions of the human immune system. Proc. 2nd International TNO Meeting on the Biology of the Interferon System, Rotterdam, April 18–22, 1983. (In press)
Einhorn, S., Blomgren, H., and Strander, H.: In vitro and in vivo effects of interferon on the mitogen responsiveness of human lymphocytes. Clin. Exp. Immunol. 1982b. (In press).
Glasgow, L.A., Crane, J.L., Schelupner, C.J., Kern, E.R., Youngner, J.S., and Feingold, D.S.: Activation of reticuloendothelial system macrophages and enhancement of host resistance to a transplantable osteogenic sarcoma in mice by an extract of Brucella abortus. Cancer Treat. Rep. 62, 1931, 1978a.
Glasgow, L., Crane, J., and Kern, E.: Antitumor activity of interferon against murine osteogenic sarcoma cells in vitro. J. Natl. Cancer Inst. 60, 659, 1978b.
Glasgow, L., Crane, J., Schleupner, C.H., Kern, E., Youngner, J., and Feingold, D.: Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus (Bru-Pel): Association with activation of reticuloendothelial system macrophages. Infect. Immun. 23, 19, 1979.
Glasgow, L. and Kern, E.: Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. J. Natl. Cancer Inst. 67, 207, 1981.
Gresser, I.: Usefulness of the results of studies on the antitumor effects of interferon in animals to interferon therapy of patients. Recent Results of Cancer Research 75, 226, 1980.
Gutterman, J.U.: Clinical investigation of the interferons in human cancer. Bulletin du Cancer 33, 271, 1981.
Ingimarsson, S.: Studies on human leukocyte interferon in clinical use. Thesis, Sundt Offset, Stockholm, 1980.
Ingimarsson, S., Cantell, K., and Strander, H.: Side effects of long-term treatment with human leukocyte interferon. J. Infect. Dis. 140, 560, 1979.
Ingimarsson, S., Cantell, K., and Strander, H.: Acute infections in patients receiving interferon. In, Interferon — Properties and Clinical Uses. Eds: A. Khan, N.O. Hill, and G.L. Dorn. Wadley Institutes, 633, 1980a.
Ingimarsson, S., Bergström, K., Broström, L.-Å., Cantell, K., and Strander, H.: Effect of long-term treatment with human leukocyte interferon on various laboratory parameters. Acta Med. Scand. 208, 155, 1980b.
Ingimarsson, S., Cantell, K., Carlström, G., and Strander, H.: Virus infections and recurrence of osteosarcoma in patients receiving human leukocyte interferon. Int. J. Cancer 26, 395, 1980c.
Ingimarsson, S., Cantell, K., Carlström, G., Dalton, B., Paucker, K. and Strander, H.: Immune reactions and long-term therapy with human leukocyte interferon. Acta Med. Scand. 209, 17, 1981.
Isaacs, A., and Lindenmann, J.: Virus interference. I. The interferons. Proc. Royal Soc. Lond. B 147, 258, 1957.
Lengyel, P.: Biochemistry of interferons and their actions. Ann. Rev. Bioch. 51, 251, 1982.
Merigan, T.C. and Friedman, R.M.: Interferons. New York & London, Academic Press, 1982.
Nilsonne, U., and Strander, H.: Clinical experience of interferon treatment in osteosarcoma. Proc. 12th Int. Immunobiological Symp. Yugoslav; Academy of Sciences and Arts Symp. on Interferon, Zagreb. 137, 1979.
Nilsonne, U. and Strander, H.: Traitement de l’osteosarcome par l’interferon et la chirurgie différenciée. Revue de Chirurgie Orthopedique 67, 193, 1981.
Priestman, T.J.: Interferons and cancer: The end of the beginning or the beginning of the end. Clin. Oncol. 7, 271, 1981.
Stewart, II, W.E.: The Interferon System. Springer-Verlag, Wien & New York, 1979.
Strander, H.: Interferons: Anti-neoplastic drugs? Blut 35, 277, 1977.
Strander, H.: Mechanisms of cell growth inhibitory and antitumor action; genetics of the interferon system. Introductory remarks. Ann. New York Acd. Sci. 350, 168, 1980.
Strander, H.: Interferon (IFN) therapy of tumor disease. Proc. Int. Workshop on Regulation and Modulation of Immune Activities. Hasliberg-Reuti, Feb. 24–27, 1981. In, Mikroökologie und Therapie, 11, 135, 1981a.
Strander, H.: Clinical trials conducted with interferon on tumour patients in Europe. TNO and Erasmus University Meeting on the Biology of the Interferon system, Rotterdam, Apr. 21–24, 1981. In, The Biology of the Interferon System. Eds.: E. De Maeyer, G. Galasso, and H. Schellekens. Elsevier/North-Holland Biomedical Press. 1981b.
Strander, H., Einhorn, S., Ingimarsson, S., Aparisi, T., Broström, L.-Å., Nilsonne, U., and Söderberg, G.: Treatment of human osteosarcoma with HU LEU IFN alpha. Presented at The Annual International Congress of Interferon Research, Miami, Nov. 1–4, 1982a.
Strander, H., and Einhorn, S.: Interferon in cancer — faith, hope and reality. Am. J. Clin. Oncol. 5, 297, 1982b.
Strander, H.: Interferon therapy for tumour diseases in man — prospects for the near future. Proc. 3rd Deutsche Stiftung für Krebsforschung, Bonn, March 13–16, 1981. In, Interferon — Properties, Mode of Action, Production, Clinical Application. Eds.: K. Munk and H. Kirchner, S. Karger, Heidelberg. 227, 1982c.
Strander, H.: Interferon therapy of malignant disease. In, The Clinical Potential of Interferons. Eds.: R. Kono and J. Vilćek. Universitv of Tokyo Press. 179, 1982d.
Strander, H.: Antitumor effects of interferon and its possible use as an antineoplastic agent. In, Texas Reports on Biology and Medicine — The Interferon System: A Review to 1982. 41 (in press) 1982e.
Strander, H.: The Role of Interferon in Disease. Cambridge University Press (in press) 1982f.
Strander, H.: Adjuvant treatment of osteosarcoma — some personal views. International Conference on Advances in the Adjuvant Therapy of Cancer. London, June 17–18. 1982g.
Strander, H. and Einhorn, S.: Effect of human leukocyte interferon on the growth of human osteogenic sarcoma cells in tissue culture. Int. J. Cancer 19, 468, 1977.
Strander, H., and Einhorn, S.: Interferon alpha trials in human tumor diseases. In, Chemistry and Biology of Interferons: Relationship to Therapeutics. UCLA Symposia on Molecular and Cellular Biology. XXV. Eds.: Thomas Merigan, Robert Friedman and C. Fox. Academic Press, New York, 399, 1982a.
Strander, H. and Einhorn, S.: Interferon therapy in neoplastic diseases. Phil. Trans. R. Soc. London. B, 299, 113, 1982b.
Strander, H., Cantell, K., Ingimarsson, S., Jakobsson, P.A., Nilsonne, U., and Söderberg, G.: Interferon treatment of osteogenic sarcoma — a clinical trial. Conf. on Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias. December 9–11, 1974. Fogarty Int. Ctr. Proc. US Govt. Printing Office, Washington, DC 28, 377, 1977.
Strander, H., Adamson, U., Aparisi, T., Broström, L.-Å., Cantell, K., Einhorn, s., Hall, K., Ingimarsson, S., Nilsome, U., and Söderberg, G.: Adjuvant interferon treatment of human osteosarcoma. In, Recent Results in Cancer Research. Eds.: G. Bonnadonna, G. Mathé and S.E. Salmon. Springer-Verlag, Berlin-Heidelberg 68, 39, 1979.
Strander, H., Aparisi, T., Blomgren, H., Broström, L.-Å., Cantell, K., Einhorn, S., Ingimarsson, S., Nilsome, U., and Söderberg, G.: Adjuvant interferon treatment of human osteosarcoma. EORTC meeting, Paris 1980. In, Recent Results in Cancer Research, Springer-Verlag, Berlin-Heidelberg, 80, 103, 1982b.
Weissmann, C., Nagata, S., Boll, W., Fountoulakis, M., Fujisawa, A., Fujisawa, J.-I., Haynes, J., Henco, K., Mantei, N., Ragg, H., Schein, C., Schmid, J., Shaw, G., Streuli, M., Taira, H., Todokoro, K., and Weidle, U.: Structure and expression of human IFN-α genes. Phil. Trans. Royal Soc., London, B, 299, 7, 1982.
WHO Scientific Group Report: Interferon therapy. Technical Report Series 676, WHO, Geneva, 1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Strander, H. et al. (1984). Adjuvant Interferon Therapy in Primary Osteosarcoma. In: Uhthoff, H.K. (eds) Current Concepts of Diagnosis and Treatment of Bone and Soft Tissue Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69210-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-69210-9_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69212-3
Online ISBN: 978-3-642-69210-9
eBook Packages: Springer Book Archive